Venus Remedies sings license agreement with lnfex Therapeutics to develop MET-X

25 Feb 2025 Evaluate

Venus Remedies has entered into an exclusive license agreement with lnfex Therapeutics, a UK-based anti-infectives specialist for the clinical development of MET-X. This agreement authorizes the company to spearhead the clinical development, registration, and commercialization of MET-X, an innovative Metallo-Beta-Lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria, with the company holding exclusive marketing rights within India.

Under the terms of the agreement, the company will commence with a Phase I involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful Phase I outcome, the focus will shift to Phase II/III trials targeting drug-resistant Complicated Urinary Tract Infections (cUTls), prevalent in hospital settings.

This strategic move is aligned with the company’s extensive experience in antibiotic R&D and critical care, enhancing its leadership in Indian critical care landscape. The company’s formidable position in meropenem marketing and manufacturing will facilitate the integration of MET-X in existing and prospective antibiotic strategies.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.

Venus Remedies Share Price

792.60 -34.60 (-4.18%)
24-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1737.50
Dr. Reddys Lab 1266.35
Cipla 1496.35
Zydus Lifesciences 917.45
Lupin 2109.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×